Cargando…
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020
Regulatory qualification of biomarkers facilitates their harmonized use across drug developers, enabling more personalized medicine. This study reviews various aspects of the European Medicines Agency’s (EMA’s) biomarker qualification procedure, including frequency and outcome, common challenges, an...
Autores principales: | Bakker, Elisabeth, Hendrikse, Natalie M., Ehmann, Falk, van der Meer, Daniëlla S., Llinares Garcia, Jordi, Vetter, Thorsten, Starokozhko, Viktoriia, Mol, Peter G.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313861/ https://www.ncbi.nlm.nih.gov/pubmed/35137949 http://dx.doi.org/10.1002/cpt.2554 |
Ejemplares similares
-
Biomarkers in Medicines Development—From Discovery to Regulatory Qualification and Beyond
por: Hendrikse, Natalie M., et al.
Publicado: (2022) -
Biomarker Qualification at the European Medicines Agency: A Look Under the Hood
por: Berman, Steven, et al.
Publicado: (2022) -
Industry perspectives on biomarker qualification
por: Lavezzari, G, et al.
Publicado: (2015) -
Perspectives on statistical strategies for the regulatory biomarker qualification process
por: Hendrix, Suzanne B, et al.
Publicado: (2021) -
Standard procedures for characterization and qualification
por: G, Viehhauser
Publicado: (2020)